• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»BioSelective Capital Investments

Why Forma Life Sciences’ U.S. CDMO launch signals renewed momentum in domestic oral solid drug manufacturing

By Pallavi Madhiraju on March 4, 2026   Pharma & Biotech  

Why Forma Life Sciences’ U.S. CDMO launch signals renewed momentum in domestic oral solid drug manufacturing

Forma Life Sciences launches a U.S. CDMO focused on oral solid drug manufacturing. Discover what the move means for pharma supply chains and drug development.

BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape

By Pallavi Madhiraju on February 5, 2026   Pharma & Biotech  

BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape

Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.

Recent Posts

  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes